866001-91-4Relevant academic research and scientific papers
GPR120 agonist as well as preparation method and application thereof
-
Paragraph 0071-0075; 0093-0094, (2021/06/02)
The invention relates to the technical field of sulfonamide compounds, and particularly provides a GPR120 agonist as well as a preparation method and application thereof. The GPR120 agonist is a compound represented by a formula (1) which is described in
INHIBITORS OF HISTONE DEACETYLASE
-
Page/Page column 114; 115, (2010/11/24)
This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I); wherein Y, L, Z, W, X, Q, R1, R2 and R3 are as defined in the specification.
INHIBITORS OF HISTONE DEACETYLASE
-
Page/Page column 141, (2010/02/14)
The invention relates to a series of compounds useful for inhibiting histone deacetylase (HDAC) enzymatic activity. The invention also provides a method for inhibiting histone descetylase in a cell using said compounds as well as a method for treating cell proliferative diseases and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compositions comprising the HDAC inhibiting compounds and a pharmaceutically acceptable carrier.
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors
Bouchain, Giliane,Leit, Silvana,Frechette, Sylvie,Abou Khalil, Elie,Lavoie, Rico,Moradei, Oscar,Woo, Soon Hyung,Fournel, Marielle,Yan, Pu T.,Kalita, Ann,Trachy-Bourget, Marie-Claude,Beaulieu, Carole,Li, Zuomei,Robert, Marie-France,MacLeod, A. Robert,Besterman, Jeffrey M.,Delorme, Daniel
, p. 820 - 830 (2007/10/03)
A series of sulfonamide hydroxamic acids and anilides have been synthesized and studied as histone deacetylase (HDAC) inhibitors that can induce hyperacetylation of histones in human cancer cells. The inhibition of HDAC activity represents a novel approach for intervening in cell cycle regulation. The lead candidates were screened in a panel of human tumor and normal cell lines. They selectively inhibit proliferation, cause cell cycle blocks, and induce apoptosis in human cancer cells but not in normal cells. The structure-activity relationships, the antiproliferative activity, and the in vivo efficacy are described.
